Dr Emily Sammons
Contact information
Emily Sammons
BSc, MBChB, MSc
MRC PHRU Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit of the University of Oxford. She has particular research interests in diabetic eye disease and age-related macular degeneration. Alongside this she works on two large randomised controlled trials: ASCEND and REVEAL. ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes. REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease. Emily has background experience of working in General Medicine and a MSc in Public Health.
Recent publications
-
ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
Journal article
SAMMONS E. et al, (2023), Contemporary Clinical Trials Communications
-
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127
-
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329
-
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
Journal article
HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424
-
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612